Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's…
4 analysts rate KYNB Buy on consensus.
Consensus price target: $38.50 (+872.22% upside from $3.96)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Wettig Thane director, CEO | Nov 17, 2025 | Purchase | 2,700 | $24.57K |
| Wettig Thane director, CEO | Nov 13, 2025 | Purchase | 1,000 | $9.18K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $6.44M | -78.26% | $183.45M |
| 2024 | $29.62M | -36.71% | $-47.58M |
| 2023 | $46.8M | -66.74% | $-284.23M |
Stock data for KYNB: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics